Antithrombotic therapy in atrial fibrillation and stent implantation: Treatment or threats by the use of triple or dual antithrombotic therapy

Thrombosis and Haemostasis

Volumn 110, Issue 4, 2013, Pages 623-625

  Marín, Francisco ^a   Huber, Kurt ^b   Lip, Gregory Y H ^c  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b Wilhelminenhospital   (Austria)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BARE METAL STENT; BLEEDING; CEREBROVASCULAR ACCIDENT; EDITORIAL; HEART ATRIUM FIBRILLATION; HEART MUSCLE ISCHEMIA; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; STENT THROMBOSIS; THROMBOEMBOLISM;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CARDIAC SURGICAL PROCEDURES; FEMALE; HUMANS; MALE; STENTS;

EID: 84884864521     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-08-0677     Document Type: Editorial

References (28)

1. Olesen JB, Lip GY, Lindhardsen J, et al. Risks ofthromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost 2011; 106: 739-749.
2. Friberg LRM, Rosenqvist M, Lip GYH. Net clinical benefit of warfarin in patients with atrial fibrillation. Circulation 2012; 125: 2298-2307.
3. Rodríguez-Mañero M, Cordero A, Bertomeu- González V, et al. Impacto de los nuevos criterios para el tratamiento anticoagulante de la fibrilación auricular. Rev Esp Cardiol 2011; 64: 649-653.
4. Wilke T, Groth A, Mueller S, et al. Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients. Thromb Haemost 2012; 107: 1053-1065.
5. Olesen JB, Torp-Pedersen C, Hansen ML, et al. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost 2012; 107: 1172-1179.
6. Olesen JB, Lip GY, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost 2011; 106: 739-749.
7. Mehta RH, Dabbous OH, Granger CB, et al; GRACE Investigators. Comparison of outcomes of patients with acute coronary syndromes with and without atrial fibrillation. Am J Cardiol 2003; 92: 1031-1036.
8. Lip GY, Andreotti F, Fauchier L, et al; European Heart Rhythm Association. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost 2011; 106: 997-1011.
9. Lip GY, Huber K, Andreotti F, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost 2010; 103: 13-28.
10. Faxon DP, Eikelboom JW, Berger PB, et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost 2011; 106: 572-584.
11. Huber K, Airaksinen KJ, Cuisset T, et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stent implantation. Thromb Hae-most 2013; 110: 560-568.
12. Bernard A, Fauchier L, Pellegrin C, et al. Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation. Thromb Haemost 2013; 110: 560-568.
13. Ruiz-Nodar JM, Marín F, Manzano-Fernandez S, et al. An evaluation of the CHADS2 stroke risk score in patients with atrial fibrillation who undergo percutaneous coronary revascularization. Chest 2011; 139: 1402-1409.
14. Ruiz-Nodar JM, Marín F, Sánchez-Payá J, et al. Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation. Eur Heart J 2009; 30: 932-939.
15. Lamberts M, Olesen JB, Ruwald MH, et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation. 2012; 126: 1185-1193.
16. Dewilde WJ, Oirbans T, Verheught F W, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomized, controlled trial. Lancet 2013; 381: 1107-1115.
17. Manzano-Fernandez S, Pastor FJ, Marín F, et al. Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting. Chest 2008; 134-. 559-567.
18. Azoulay L, Dell'Aniello S, Simon T, et al. The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillation. Thromb Haemost 2013; 109: 431-439.
19. Manzano-Fernández S, Cambronero F, Caro-Martínez C, et al. Mild kidney disease as a risk factor for major bleeding in patients with atrial fibrillation undergoing percutaneous coronary stenting.Thromb Haemost 2012; 107: 51-58.
20. Smith JG, Wieloch M, Koul S, et al. Triple anti-thrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score. EuroIntervention 2012; 8: 672-678.
21. Ruiz-Nodar JM, Marín F. Antithrombotic therapy and bleeding risk in atrial fibrillation. Fewer unanswered questions. Thromb Haemost 2013; 109: 363-365.
22. Brugaletta S, Garcia-Garcia HM, Onuma Y, Ser-ruys PW. Everolimus-eluting ABSORB bioresorb-able vascular scaffold: present and future perspectives. Expert Rev Med Devices 2012; 9: 327-38.
23. Colmenarez H, Fernández C, Escaned J. Impact of technological developments in drug-eluting stents on patient-focused outcomes: a pooled direct and indirect comparison of randomised trials comparing first- and second-generation drug-eluting stents. EuroIntervention 2013; Epub ahead of print.
24. Costopoulos C, Latib A, Naganuma T, et al. Comparison of abluminal biodegradable polymer bioli-mus-eluting stents and durable polymer everoli-mus-eluting stents in the treatment of coronary bifurcations. Catheter Cardiovasc Interv 2013; Epub ahead of print.
25. Banerjee A, Lane D, Torp-Pedersen C, et al. Net clinical benefit of new oral anticoagulants (dabi-gatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modeling analysis based on a nationwide cohort study. Thromb Haemost 2012; 107: 584-589.
26. Huisman MV, Lip GY, Diener HC, et al. Dabi-gatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012; 107: 838-847.
27. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747.
28. Kirchhof P, Lip GY, Van Gelder IC, et al. Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conference. Thromb Haemost 2011; 106: 1012-1019.